313 related articles for article (PubMed ID: 29381666)
1. Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials.
Swica Y; Warren MP; Manson JE; Aragaki AK; Bassuk SS; Shimbo D; Kaunitz A; Rossouw J; Stefanick ML; Womack CR
Menopause; 2018 Jul; 25(7):753-761. PubMed ID: 29381666
[TBL] [Abstract][Full Text] [Related]
2. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Manson JE; Chlebowski RT; Stefanick ML; Aragaki AK; Rossouw JE; Prentice RL; Anderson G; Howard BV; Thomson CA; LaCroix AZ; Wactawski-Wende J; Jackson RD; Limacher M; Margolis KL; Wassertheil-Smoller S; Beresford SA; Cauley JA; Eaton CB; Gass M; Hsia J; Johnson KC; Kooperberg C; Kuller LH; Lewis CE; Liu S; Martin LW; Ockene JK; O'Sullivan MJ; Powell LH; Simon MS; Van Horn L; Vitolins MZ; Wallace RB
JAMA; 2013 Oct; 310(13):1353-68. PubMed ID: 24084921
[TBL] [Abstract][Full Text] [Related]
3. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL
JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007
[TBL] [Abstract][Full Text] [Related]
4. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Rohan TE; Manson JE; Aragaki AK; Kaunitz A; Stefanick ML; Simon MS; Johnson KC; Wactawski-Wende J; O'Sullivan MJ; Adams-Campbell LL; Nassir R; Lessin LS; Prentice RL
JAMA Oncol; 2015 Jun; 1(3):296-305. PubMed ID: 26181174
[TBL] [Abstract][Full Text] [Related]
6. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.
Manson JE; Aragaki AK; Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Chlebowski RT; Howard BV; Thomson CA; Margolis KL; Lewis CE; Stefanick ML; Jackson RD; Johnson KC; Martin LW; Shumaker SA; Espeland MA; Wactawski-Wende J;
JAMA; 2017 Sep; 318(10):927-938. PubMed ID: 28898378
[TBL] [Abstract][Full Text] [Related]
7. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
Espeland MA; Rapp SR; Shumaker SA; Brunner R; Manson JE; Sherwin BB; Hsia J; Margolis KL; Hogan PE; Wallace R; Dailey M; Freeman R; Hays J;
JAMA; 2004 Jun; 291(24):2959-68. PubMed ID: 15213207
[TBL] [Abstract][Full Text] [Related]
8. Effects of estrogen with and without progestin on urinary incontinence.
Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
[TBL] [Abstract][Full Text] [Related]
9. The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials.
Jiang X; Aragaki AK; Nudy M; Manson JE; Shadyab AH; Wild RA; Valdiviezo C; Gass M; Martin LW; Pan K; Stefanick ML; Robbins JA; Schnatz PF
Menopause; 2023 Jan; 30(1):28-36. PubMed ID: 36256926
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA
Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929
[TBL] [Abstract][Full Text] [Related]
11. Menopausal estrogen therapy and non-Hodgkin's lymphoma: A post-hoc analysis of women's health initiative randomized clinical trial.
Kato I; Chlebowski RT; Hou L; Wactawski-Wende J; Ray RM; Abrams J; Bock C; Desai P; Simon MS
Int J Cancer; 2016 Feb; 138(3):604-11. PubMed ID: 26365326
[TBL] [Abstract][Full Text] [Related]
12. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML;
JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414
[TBL] [Abstract][Full Text] [Related]
13. Menopausal Hormone Therapy and Risks of First Hospitalized Heart Failure and its Subtypes During the Intervention and Extended Postintervention Follow-up of the Women's Health Initiative Randomized Trials.
Liu L; Klein L; Eaton C; Panjrath G; Martin LW; Chae CU; Greenland P; Lloyd-Jones DM; Wactawski-Wende J; Manson JE
J Card Fail; 2020 Jan; 26(1):2-12. PubMed ID: 31536806
[TBL] [Abstract][Full Text] [Related]
14. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Pickar JH; Yeh I; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2001 Jul; 76(1):25-31. PubMed ID: 11438315
[TBL] [Abstract][Full Text] [Related]
15. Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative.
Al-Rousan T; Sparks JA; Pettinger M; Chlebowski R; Manson JE; Kauntiz AM; Wallace R
PLoS One; 2018; 13(12):e0207509. PubMed ID: 30513095
[TBL] [Abstract][Full Text] [Related]
16. Effect of estrogen therapy on gallbladder disease.
Cirillo DJ; Wallace RB; Rodabough RJ; Greenland P; LaCroix AZ; Limacher MC; Larson JC
JAMA; 2005 Jan; 293(3):330-9. PubMed ID: 15657326
[TBL] [Abstract][Full Text] [Related]
17. Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice.
Panay N; Nappi RE; Stute P; Palacios S; Paszkowski T; Kagan R; Archer DF; Héroux J; Boolell M
Maturitas; 2023 Jun; 172():23-31. PubMed ID: 37084589
[TBL] [Abstract][Full Text] [Related]
18. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding.
Archer DF; Dorin M; Lewis V; Schneider DL; Pickar JH
Fertil Steril; 2001 Jun; 75(6):1080-7. PubMed ID: 11384630
[TBL] [Abstract][Full Text] [Related]
19. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.
LaCroix AZ; Chlebowski RT; Manson JE; Aragaki AK; Johnson KC; Martin L; Margolis KL; Stefanick ML; Brzyski R; Curb JD; Howard BV; Lewis CE; Wactawski-Wende J;
JAMA; 2011 Apr; 305(13):1305-14. PubMed ID: 21467283
[TBL] [Abstract][Full Text] [Related]
20. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.
Pickar JH; Yeh IT; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2003 Nov; 80(5):1234-40. PubMed ID: 14607581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
